Maravai LifeSciences Presents 20% Growth in Year-to-Date Revenue to $163.1 Million
Bitget2026/11/05 22:50- Maravai LifeSciences reported year-to-date 2026 revenue of $163.1 million, up 20%, in an investor presentation.
- Adjusted EBITDA reached $34.8 million, with an adjusted gross margin of 61.1%.
- TriLink base revenue rose 13% year over year, driven by mRNA growth; Cygnus revenue increased 4%, its sixth consecutive quarterly gain.
- Cost reductions exceeded $65 million under the corporate realignment plan, surpassing the initial target of more than $50 million.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
British Pound hits session highs at 1.3420 amid broadbased US Dollar weakness
Cybertruck orders far exceed pre-production capacity, Tesla (TSLA.US) to refund deposits to a large number of customers
Elon Musk stated that Tesla will refund the Cybertruck deposits to a significant number of customers.
Barrick Gold (B.US) Q3 Results Mixed: Benefiting from Gold Price Dividend While Facing Cost Pressures
Barrick Mining (B.US) will release its financial results for the third quarter of 2026 before the U.S. stock market opens on November 9.
Crypto prices
More
